Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial
Authors:
- Frédérique Penault-LlorcaFPFrédérique Penault-Llorca
- Amelie LusqueALAmelie Lusque
- Thomas FilleronTFThomas Filleron
- Kevin TranKTKevin Tran
- Lili DuLDLili Du
- Rick BaehnerRBRick Baehner
- Florence DalencFDFlorence Dalenc
- Magali Lacroix-TrikiMLMagali Lacroix-Triki
- Thomas BachelotTBThomas Bachelot
- Fabrice AndreFAFabrice Andre
- Pascal BoucherPBPascal Boucher
- Jérôme LemonnierJLJérôme Lemonnier
Open Access
- 7 August 2026
- journal article
- Published by Elsevier in The Breast
- Vol. 89
Abstract
No abstract availableFunding Information
- Sanofi France
- Cancer Prevention and Research Institute of Texas (RP#180712)
- Breast Cancer Research Foundation (BCRF-158)
- Ligue Contre le Cancer
- Pfizer France
This publication has 26 references indexed in Scilit:
- Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trialEuropean Journal of Cancer, 2025
- Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trialsThe Lancet, 2023
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast CancerNew England Journal of Medicine, 2021
- Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapyAnnals of Oncology, 2021
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerNew England Journal of Medicine, 2018
- 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG OncologyBreast Cancer Research and Treatment, 2017
- PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)npj Breast Cancer, 2016
- PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancerBreast Cancer Research and Treatment, 2013
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancerProceedings of the National Academy of Sciences, 2005